Reply to: Correspondence on "Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection"
- PMID: 35987276
- DOI: 10.1016/j.jhep.2022.07.032
Reply to: Correspondence on "Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection"
Conflict of interest statement
Conflict of interest No industry funded or supported this study. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment on
-
Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.J Hepatol. 2022 Oct;77(4):939-946. doi: 10.1016/j.jhep.2022.05.014. Epub 2022 May 26. J Hepatol. 2022. PMID: 35643206
-
HBsAg seroclearance and reduction in late recurrence of HBV-related HCC: Causality or co-existence?J Hepatol. 2022 Nov;77(5):1468-1469. doi: 10.1016/j.jhep.2022.06.009. Epub 2022 Jun 19. J Hepatol. 2022. PMID: 35732214 No abstract available.
-
HBsAg seroclearance reduces the risk of late recurrence in HBV-related HCC.J Hepatol. 2022 Nov;77(5):1469-1470. doi: 10.1016/j.jhep.2022.06.030. Epub 2022 Jul 8. J Hepatol. 2022. PMID: 35810929 No abstract available.
-
Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma.J Hepatol. 2022 Nov;77(5):1471-1472. doi: 10.1016/j.jhep.2022.07.005. Epub 2022 Jul 19. J Hepatol. 2022. PMID: 35863489 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
